All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | JUN 2024 ~1.3:1 split | JUN 2023 | JUN 2022 | JUN 2021 | JUN 2020 ~1.4:1 split |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $2 | $2 | $3 | $3 | $1 | $0 |
| Cost of Revenue | $2 | $2 | $3 | $2 | $1 | $0 |
| Gross Profit | $0 | $0 | $1 | $1 | $1 | $0 |
| General & Administrative | $17 | $20 | $29 | $40 | $23 | $6 |
| Research & Development | $7 | $9 | $14 | $15 | $10 | $5 |
| Total Operating Expenses | $25 | $30 | $43 | $54 | $33 | $10 |
| Operating Income | -$25 | -$30 | -$42 | -$53 | -$32 | -$10 |
| Other Non-Operating Income (Expense) | $0 | $0 | $1 | $10 | -$8 | $1 |
| EBT (Earnings Before Tax) | -$28 | -$33 | -$46 | -$45 | -$35 | -$10 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Minority Interest | – | – | – | $0 | $1 | $0 |
| Net Income | ||||||
| Net Income | -$28 | -$33 | -$46 | -$45 | -$35 | -$10 |
| Per Share Data | ||||||
| Revenue Per Share | $0.02 | $0.02 | $0.04 | $0.04 | $0.02 | $0.00 |
| EPS (Basic) | -$0.24 | -$0.31 | -$0.55 | -$0.62 | -$0.49 | -$0.17 |
| EPS (Diluted) | -$0.24 | -$0.31 | -$0.55 | -$0.67 | -$0.49 | -$0.17 |
| Weighted Avg Shares (Basic) | 105.7M | 108.2M | 82.2M | 72.9M | 71.5M | 59.1M |
| Weighted Avg Shares (Diluted) | 105.7M | 108.2M | 82.2M | 73.8M | 71.5M | 59.1M |
| Shares Outstanding | 105.7M | 108.2M | 82.2M | 73.8M | 71.5M | 59.1M |
Renalytix (RENXF) financials: revenue, profit and margins
Renalytix (RENXF) generated about $2 million in revenue and -$28 million in net income (a -1,191.8% net margin) over the trailing twelve months, growing at roughly 15.4% a year. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
What is Renalytix's (RENXF) revenue?+
Renalytix generated about $2 million in revenue over the trailing twelve months. Revenue has grown at roughly 15.4% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Renalytix profitable?+
Renalytix reported about -$28 million in net loss over the trailing twelve months, a net margin of roughly -1,191.8%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Renalytix's profit margins?+
Renalytix runs a gross margin of about 12.7%, an operating margin of about -1,054.9%, a net margin of about -1,191.8%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Renalytix growing?+
Renalytix's revenue has compounded at roughly 15.4% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside RENXF's margins and free cash flow. This is analysis from SEC filings, not investment advice.
SourceFinancial statements computed from the 10-Q filed 7 Nov 2024, covering the period ending 30 Sept 2024, as reported to the SEC. Data last refreshed 17 Aug 2026. How this is calculated.
Fiscal year ends Jun.
Peers
Services-Medical Laboratories · Pick stocks to compare with RENXF
Spot a number that looks wrong? Check it in RENXF's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing RENXF
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.